Immunization

The federal government is actively looking to enhance its evolving approach toward US childhood vaccine recommendations.

Pfizer and BioNTech, Moderna, Sanofi, and Takeda received FDA approval for updated 2026-2027 COVID-19 vaccines reformulated to target the XFG variant.

New consensus confirms that chronic obstructive pulmonary disease, asthma, bronchiectasis, and lung cancer are indications for pneumococcal vaccination.

Focusing on serotype distribution, resistance trends, and vaccination impact, researchers analyze invasive pneumococcal disease burden.

A tool now tracks measles, meningitis, and whooping cough at the state and substate level, giving pharmacists a new resource to identify local outbreaks.

Giving 15-valent pneumococcal conjugate vaccine alongside acellular DTaP did not compromise antibody responses to either vaccine.

Through the scope of Nigerian pharmacists and their vaccination rates, researchers assessed strategies for advancing public health.

Among COVID-19 vaccine recipients, researchers assess the safety and efficacy of the 2023-24 protein-based and mRNA COVID-19 vaccines.

Pharmacists navigate ACIP changes, legal battles, and shifting vaccine schedules reshaping US immunization policy and respiratory season planning.

Across 3 survey periods spanning 2017 to 2023, researchers assess various institutions’ knowledge of pneumococcal vaccination.

A cohort of Black and white Americans was asked about medical racism, misinformation, COVID-19 vaccine safety, and more.

A year of ACIP turnover, schedule changes, and lawsuits has fractured US vaccine guidance—and tied pharmacists' scope and billing to a moving target.

The academy's updated influenza guidance arrives days after a White House executive order narrowed the recommended childhood vaccine schedule.

The White House and the American Academy of Pediatrics leave pharmacists navigating 2 competing sets of vaccine guidance for the upcoming season.

A decades-long research effort in mRNA-produced licensed vaccines targets influenza, respiratory syncytial virus, cytomegalovirus, HIV, and cancer.

Researchers aimed to better understand the prominence of vaccine failures and breakthrough infections of pediatric pneumoccoal immunization.

Community pharmacists deliver travel vaccine clinics, navigate entry rules, and update routine shots with new guidance on polio, measles, and chikungunya.

Data on excess deaths in high-income countries show the male mortality disadvantage during COVID-19 is concentrated in the pandemic's earliest phase.

The approval gives pharmacists a new, nonegg-based seasonal influenza option for adults 50 and older ahead of the 2026-2027 flu season.

Researchers highlight the importance of vaccination for the risk reduction needed across the pediatric population.

Centuries of vaccine science saved more lives than any other intervention, and pharmacists matter now more than ever.

As COVID-19 shifts from emergency response to routine care, persistent inequities in vaccine access are quietly resurfacing.

Newly filed charters arrive as pharmacy groups already press HHS over similar changes to the CDC's vaccine advisory panel.

A study found antibody deficiencies and monoclonal immunoglobulins in a share of adults hospitalized with invasive pneumococcal disease.

A 4-year cohort study finds pneumococcal vaccine serotypes circulating and increasing among older adults with community-acquired pneumonia.